Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 7/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914123 | 1.00 | MAPK14 (0.36) | MAPK14DYRK1BKDRMAPK1FGFR1 | |
| SCHEMBL5317902 | 0.85 | KDR (0.38) | MAPK14KDR | |
| SCHEMBL5914283 | 0.85 | KDR (0.36) | MAPK14DYRK1BKDRFGFR1EPHB4 | |
| SCHEMBL5914286 | 0.85 | KDR (0.36) | MAPK14DYRK1BKDRFGFR1EPHB4 | |
| SCHEMBL5914049 | 0.85 | CFD (0.38) | MAPK14DYRK1BKDRMAPK1FGFR1 | |
| SCHEMBL5914043 | 0.85 | CFD (0.38) | MAPK14DYRK1BKDRMAPK1FGFR1 | |
| SCHEMBL5263171 | 0.85 | MAPK14 (0.36) | MAPK14KDRMAPK1KITPDGFRA | |
| SCHEMBL5317904 | 0.85 | KDR (0.38) | MAPK14KDRFGFR1EPHB4 | |
| SCHEMBL5914154 | 0.84 | MAPK14 (0.36) | MAPK14KDR | |
| SCHEMBL5914280 | 0.84 | MAPK14 (0.36) | MAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | claimed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | MAPK14 2620/4885DYRK1B 2594/4885KDR 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.